Steinhart Richard I (CIK 1293789) reported 16 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-09-04). Recent activity: Buy ATNM (62,800 shares), Buy BTAI (35 shares), Buy BTAI (17,500 shares), Sell BTAI (6,845 shares), Buy ATOS (10,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Actinium Pharmaceuticals, Inc. (ATNM) | Director | Buy | 62,800 | $0 |
| 2026-06-17 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 35 | $0 |
| 2026-05-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 17,500 | $0 |
| 2026-05-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Sell | 6,845 | $7,461 |
| 2026-05-14 | ATOSSA THERAPEUTICS, INC. (ATOS) | Director | Buy | 10,000 | $0 |
| 2026-05-07 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 9,000 | $0 |
| 2026-03-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 33 | $0 |
| 2026-03-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 35 | $0 |
| 2025-12-15 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 33 | $0 |
| 2025-12-15 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 35 | $0 |
| 2025-09-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 33 | $0 |
| 2025-09-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 35 | $0 |
| 2025-07-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 4,375 | $0 |
| 2025-07-22 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 625 | $0 |
| 2025-06-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 33 | $0 |
| 2025-06-16 | BioXcel Therapeutics, Inc. (BTAI) | Chief Financial Officer | Buy | 35 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-04